

Lung Transplant Continuous Distribution

Opportunities for Continuous Improvement

Heather Strah

Internal Medicine: Pulmonary, Critical Care and Sleep



University of Nebraska
Medical Center

Disclosures

I have no financial relationships with any ACCME ineligible companies.

Objectives

- Compare the previous lung allocation score with current composite allocation score
- Dissect the current composite allocation score attributes
- Address the urgent ABO modification
- Explore opportunities for further optimization for biologically disadvantaged candidates




Lung Transplantation


- Surgical treatment for end-stage lung disease
 - Interstitial and fibrotic lung disease (~50% of lung transplants)
 - COPD
 - Pulmonary hypertension
 - All other lung diseases
 - Cystic Fibrosis
- Extend life and improve quality
- Lowest survival of any solid organ transplant
 - Waitlist
 - 1-year
 - Long-term



Evolution of Lung Allocation




Priorities of the Lung Community



Miller, E. Public Comment Proposal: Establish Continuous Distribution of Lungs. 2021.




Priorities of the Lung Community



Miller, E. Public Comment Proposal: Establish Continuous Distribution of Lungs. 2021.




Priorities of the Lung Community



Miller, E. Public Comment Proposal: Establish Continuous Distribution of Lungs. 2021.




Priorities of the Lung Community



Miller, E. Public Comment Proposal: Establish Continuous Distribution of Lungs. 2021.




Priorities of the Lung Community



Miller, E. Public Comment Proposal: Establish Continuous Distribution of Lungs. 2021.




Priorities of the Lung Community



Miller, E. Public Comment Proposal: Establish Continuous Distribution of Lungs. 2021.



Priorities of the Lung Community




Miller, E. Public Comment Proposal: Establish Continuous Distribution of Lungs. 2021.




Comparison of Two Allocation Scores

LAS




CAS



Waitlist Survival

- Age
- Bilirubin
- BMI
- Assisted Ventilation
- Creatinine
- Diagnosis group
- Functional status
- Oxygen need at rest
- pCO₂
- pCO₂ increase of at least 15%
- PA systolic pressure
- Six-minute walk distance




*Candidates at least 12 years old

Miller, E. Public Comment Proposal: Establish Continuous Distribution of Lungs. 2021.



Post Transplant Survival

- Age
- Creatinine
- Cardiac Index
- Assisted ventilation
- Diagnosis group
- Functional status
- Six-minute walk distance




*Candidates at least 12 years old

Miller, E. Public Comment Proposal: Establish Continuous Distribution of Lungs. 2021.


Scoring Simulations: Waitlist Urgency

WLS PTS Bio PLD Pedi Eff



Number of
waitlist deaths

LAS




1:1 Waitlist survival:
Post-transplant
survival

2:1 Waitlist survival:
Post-transplant
survival



Scoring simulations: Post-transplant Survival


WLS PTS Bio PLD Pedi Eff



1:1 Waitlist
Survival: Post-
transplant Survival

1:1 Waitlist
Survival: Post-
transplant Survival

Transplants per
patient year



LAS


2:1 Waitlist
Survival: Post-
transplant Survival

2:1 Waitlist
Survival: Post-
transplant Survival




Aspirational transplant equity

Transplants per
patient year




Increased transplant rate

Figure 2: Lung Transplants per 100 Patient Years on the Waiting List by Era



Reduced waitlist mortality

Figure 1: Deaths or Removals for Too Sick per 100 Patient Years on the Waiting List by Era



Faster transplants for sickest patients

- Medical urgency curve demonstrates right-skewed distribution
- Candidates with medical urgency scores above the 95th percentile have median wait time less than a week.

Summary of Medical Urgency Goal Points and Percentage of Goal

Medical Urgency	Number Waiting	25th percentile	Median	75th percentile	90th percentile	95th percentile	99th percentile
Number of Points	972	0.1275	0.3275	0.8950	1.4750	2.5700	18.9475
Percentage of Goal	972	0.5100%	1.3100%	2.7800%	3.9000%	10.2800%	75.7900%

Figure 5: Median Time to Transplant (Days) by Medical Urgency Points at Listing in the Post Policy Era





Table 5: Median Time to Transplant (Days) by Medical Urgency Points at Listing in the Post Policy Era


Medical Urgency Points at Listing	N Registrations	Median Time to Transplant (Days)
<0.5	1731	53
>=0.5, <1	835	49
>=1, <2.5	174	26
>=2.5	576	6

The biological disadvantages miss

Transplants by Blood Group




Changes to Blood Group Allocation



Composite Allocation Score


CAS



Why the miss? One Scale

Figure 12. Shape of Biological Disadvantages Rating Scales⁶⁰


Percentage
of population
incompatible



Percentage
of GOAL


Why the miss? One Scale

Figure 12. Shape of Biological Disadvantages Rating Scales⁶⁰




Why the miss? One Scale

Figure 12. Shape of Biological Disadvantages Rating Scales⁶⁰




Why the miss? One Scale

Figure 12. Shape of Biological Disadvantages Rating Scales⁶⁰




Why the miss? One Scale

Figure 12. Shape of Biological Disadvantages Rating Scales⁶⁰



Why the miss? One Scale


Figure 12. Shape of Biological Disadvantages Rating Scales⁶⁰



Why the Urgency?


- Type O medical urgency points = 1.2325 vs type B 0.6200
- Type O wait time increased
- Post-policy 21% increase in O donor allocation to non-O recipients

Figure 7. Proposed Blood Type Rating Scale




Persistent discrepancies

- What is the maximum transplant rate for blood group O candidates?



Height disparities for the short

- Who is in our donor pool?



Biological Disadvantages

- Single Donor Pool

Height

PRA

Blood type

Donor
Pool



Biological Disadvantages

- Single Donor Pool

Height

PRA


Blood type

Blood
type




Biological Disadvantages

- Single Donor Pool




Biological Disadvantages

- Single Donor Pool



Future directions

- Better define the donor pool to determine the appropriate distribution of biological disadvantages points



Conclusion

- Continuous distribution has improved waitlist mortality and transplant rates for lung transplant candidates in the US
- Disparities for the biologically disadvantaged persist and more knowledge is needed to optimize the allocation system to eliminate disparities
- Additional downstream effects, like increases in out-of-sequence allocation, require in-depth exploration to understand the complex drivers behind OPO and transplant program behaviors while still meeting the needs of both recipients and donor families



Acknowledgements

- Maryam Valapour, MD
- Erika Lease, MD
- Marie Budev, MD
- Samantha Weiss, MS
- Chelsea Hawkins, PhD
- OPTN Lung Committee
- SRTR and UNOS support staff to the OPTN Lung Committee
- Danny Hershberger, MD





University of Nebraska
Medical Center

UNIVERSITY OF
Nebraska
Medical Center

